Your browser doesn't support javascript.
loading
A case report: Nonsecretory multiple myeloma presenting with bone pain.
Geng, Qianshuang; Li, Jie; Li, Xi; Zhang, Wenjie; Zhang, Guoxiang; Ge, Li; Liang, Li.
Afiliación
  • Geng Q; Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China.
  • Li J; Department of Oncology and Hematology, Liuyang Hospital of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China.
  • Li X; Department of Nephrology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China.
  • Zhang W; Department of Image, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China.
  • Zhang G; Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China.
  • Ge L; Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China.
  • Liang L; Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China.
Medicine (Baltimore) ; 103(5): e36951, 2024 Feb 02.
Article en En | MEDLINE | ID: mdl-38306571
ABSTRACT
RATIONALE Nonsecretory multiple myeloma (NSMM) is a rare subtype of multiple myelom, occurring in 1% to 2% of multiple myelom and characterized by the inability of clonal plasma cells to synthesize or secrete immunoglobulins. We describe a 71-year-old male patient who began with bone pain and was referred to hospital several times, but was not properly diagnosed and effectively treated. PATIENT CONCERNS A 71-year-old male patient visited our hematology department, complaining of lumbago for 1 year and back pain for half a year. DIAGNOSES Low-dose whole-body bone computed tomography multiple bone destruction of the sternum, ribs, multiple vertebrae and accessories of the spine, pelvis, bilateral humerus, and proximal femur. Monoclonal plasma cells accounted for 17.5% of nuclear cells in bone marrow puncture smear. Fluorescence in situ hybridization detected amplification of CKS1B (1q21) gene. Immunofixation electrophoresis negative. About 10.72% of monoclonal plasma cells were detected by flow cytometry. Finally, he was diagnosed with NSMM.

INTERVENTIONS:

The patients received VCD chemotherapy (bortezomib 1.3 mg/m2, d1, d4, d8, d11; cyclophosphamide 300 mg/m2, d1-2, d8-9; dexamethasone sodium phosphate 20 mg, d1-2, d4-5, d8-9, d11-12, once every 21 days).

OUTCOMES:

After 2 cycles of VCD treatment, the symptoms of bone pain were significantly relieved, and the efficacy was evaluated as partial response. Follow-up chemotherapy will continue to be completed on schedule. We will continue to follow up to further evaluate the overall survival and progression-free survival. LESSONS This case shows that NSMM is easily missed or misdiagnosed.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Diagnostic_studies Límite: Aged / Humans / Male Idioma: En Revista: Medicine (Baltimore) Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Diagnostic_studies Límite: Aged / Humans / Male Idioma: En Revista: Medicine (Baltimore) Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos